GO:0035197 siRNA binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035197 (siRNA binding) is a molecular function describing the binding of a protein to a small interfering RNA of 21-23 nucleotides, the product of dsRNA processing by an RNAse enzyme.
• Argonaute proteins are the central siRNA-binding effectors that load siRNA duplexes and use the guide strand to recognize complementary mRNA targets.
• In C. elegans, the RNA-binding protein RDE-4 is required for Argonaute-siRNA loading, linking siRNA binding to the broader RNAi machinery.
• Synthetic siRNA binding by delivery vehicles and conjugates such as lipid nanoparticles, GalNAc conjugates, Bicycle peptides, and protein nanocarriers determines therapeutic potency and tissue targeting [1,2,3,7,8].
• Seed-pairing destabilization of GalNAc-siRNA conjugates improves clinical safety by reducing off-target binding while preserving on-target siRNA binding.
• Polymer-siRNA binding strength alone does not predict polyplex-mediated silencing, showing that binding must be interpreted within cellular context.
Description
GO:0035197, siRNA binding, is a molecular function defined as binding to a small interfering RNA, a 21-23 nucleotide RNA processed from double-stranded RNA by an RNAse enzyme. This function sits at the heart of RNA interference, where a loaded guide strand directs sequence-specific silencing of complementary transcripts. Researchers studying gene regulation, antiviral defense, and RNAi therapeutics must understand siRNA binding because it determines which transcripts are recognized and how efficiently silencing occurs. The function is not limited to endogenous Argonaute proteins; it also describes the interaction of synthetic siRNAs with delivery systems, including lipid nanoparticles, GalNAc conjugates, and peptide or protein carriers [1,2,3,7,8]. Because siRNA binding is the first committed step in RNAi, it is a focal point for both mechanistic studies and therapeutic optimization [4,5].
siRNA binding At A Glance
| GO ID | GO:0035197 |
|---|---|
| GO term | siRNA binding |
| Ontology | molecular_function |
| Synonym | small interfering RNA binding |
| Definition | Binding to a small interfering RNA, a 21-23 nucleotide RNA that is processed from double stranded RNA (dsRNA) by an RNAse enzyme. |
| Major function | Recognition and loading of siRNA guides for RNA interference and for synthetic siRNA delivery. |
| Ligand class | Small interfering RNA, 21-23 nucleotides. |
| Representative proteins | Argonaute proteins and the RNA-binding protein RDE-4. |
| Therapeutic relevance | Lipid nanoparticles, GalNAc conjugates, Bicycle peptides, and protein nanocarriers bind siRNA to enable RNAi therapy [1,2,3,7,8]. |
What Is GO:0035197?
siRNA binding (GO:0035197) is the molecular function of selectively and non-covalently interacting with a small interfering RNA. The ligand is a 21-23 nucleotide RNA generated by an RNAse enzyme from double-stranded RNA. This function is distinct from general RNA binding because it specifies the siRNA length class and its role in RNAi. Proteins with this activity include Argonaute family members that load siRNA duplexes and retain the guide strand for target recognition. The term also applies to engineered or natural macromolecules that bind siRNA for delivery, stabilization, or cellular uptake [1,2,3,6,7,8].
Why Is siRNA binding Important in Cell Biology?
siRNA binding is important because it is the molecular decision point that commits a cell or a therapeutic formulation to RNAi. In endogenous pathways, Argonaute loading of siRNA determines which mRNAs are silenced, influencing development, genome stability, and antiviral responses. In medicine, the binding properties of delivery vehicles and conjugates dictate biodistribution, potency, and safety of siRNA drugs [1,2,3,5,7,8]. Understanding siRNA binding therefore connects basic RNA biology to clinical translation.
• Defines the first step of RNA interference, where guide-strand selection determines target specificity.
• Enables sequence-specific gene knockdown for functional genomics and target validation.
• Underpins therapeutic siRNA delivery by lipid nanoparticles in cancer treatment.
• Explains tissue targeting of GalNAc-siRNA conjugates for liver-directed RNAi therapeutics.
• Supports enhanced potency in skeletal and cardiac muscle through transferrin receptor 1-binding Bicycle peptide conjugation.
• Informs clinical safety through seed-pairing destabilization that reduces off-target siRNA binding.
• Clarifies that polymer-siRNA binding strength alone does not guarantee polyplex-mediated silencing.
• Enables lysosomal escape and targeted RNAi therapy in glioblastoma using bioengineered protein nanocarriers.
• Provides design rules for hexahistidine-metal assembly with RNA-binding and endosomal escape peptides.
• Links siRNA binding to disease areas including cancer, neuromuscular disorders, and metabolic disease [1,2,3,7].
Molecular Mechanism of siRNA binding
Argonaute loading of siRNA duplexes
In simple terms: A protein called Argonaute picks up the siRNA and keeps one strand as a guide.
Argonaute proteins are the principal effectors that bind siRNA duplexes and retain one strand as the guide. In C. elegans, Argonaute-siRNA loading requires the RNA-binding protein RDE-4, which associates with the RNAi machinery to facilitate guide-strand handoff. This loading step defines the molecular function GO:0035197 because it is the physical binding of a 21-23 nucleotide siRNA by a protein. Once loaded, the guide strand directs base pairing with complementary mRNA, leading to silencing.
Guide-strand selection and seed pairing
In simple terms: The siRNA uses a short seed sequence to find matching messenger RNAs.
After binding, the siRNA guide strand presents a seed region that mediates initial pairing with target transcripts. Seed-pairing interactions are central to target recognition, and destabilizing the seed can reduce off-target binding while preserving on-target activity. This principle has been applied to GalNAc-siRNA conjugates to improve clinical safety, showing that the binding interface between siRNA and its partners is tunable.
Synthetic siRNA binding by delivery vehicles
In simple terms: Man-made carriers grab the siRNA to carry it into cells.
Lipid nanoparticles bind and encapsulate siRNA for cancer treatment, protecting the RNA and promoting cellular uptake. GalNAc conjugates bind siRNA through multivalent carbohydrate display to enable hepatocyte targeting. Bicycle peptides conjugated to siRNA bind transferrin receptor 1 and enhance potency in skeletal and cardiac muscles. Protein nanocarriers have been engineered to bind siRNA and facilitate lysosomal escape for glioblastoma therapy. Hexahistidine-metal assemblies combined with RNA-binding and endosomal escape peptides improve siRNA delivery.
Binding affinity versus functional silencing
In simple terms: Strong binding does not always mean strong gene silencing.
Modulating polymer-siRNA binding does not necessarily promote polyplex-mediated silencing, indicating that binding affinity must be balanced with intracellular release and processing. This finding highlights that GO:0035197 describes a binding event whose functional consequence depends on downstream steps such as endosomal escape, disassembly, and Argonaute loading [6,7].
Cofactors and regulation of siRNA binding
In simple terms: Other proteins and RNA features help or hinder siRNA binding.
RDE-4 is a required cofactor for Argonaute-siRNA loading in C. elegans, demonstrating that accessory RNA-binding proteins regulate this molecular function. In therapeutic settings, chemical modifications such as seed-pairing destabilization modulate binding specificity and safety. Delivery peptides and metal assemblies can also be viewed as cofactors that influence siRNA binding and trafficking.
Key Genes Involved in GO:0035197 siRNA binding
The following genes and proteins represent major contributors to siRNA binding, spanning endogenous RNAi effectors and synthetic delivery components.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AGO1 | Argonaute family protein that binds small RNAs | Core siRNA binding effector in RNAi |
| AGO2 | Argonaute family protein that binds siRNA and cleaves targets | Central to siRNA-guided silencing |
| RDE-4 | RNA-binding protein required for Argonaute-siRNA loading | C. elegans model of siRNA loading |
| DCR-1 | Dicer ribonuclease that processes dsRNA to siRNA | Generates the 21-23 nucleotide siRNA ligand |
| TFR1 | Transferrin receptor 1 targeted by Bicycle peptides | Enhances siRNA potency in muscle |
| ASGPR | Asialoglycoprotein receptor for GalNAc conjugates | Mediates hepatocyte uptake of GalNAc-siRNA |
| LNP components | Lipid nanoparticle formulation that binds siRNA | Cancer siRNA delivery |
| Polymer carriers | Synthetic polymers that bind siRNA | Polyplex-mediated silencing studies |
| Protein nanocarriers | Bioengineered proteins that bind siRNA | Glioblastoma RNAi therapy |
| Hexahistidine-metal assembly | Inorganic-protein assembly for siRNA binding | Endosomal escape and delivery |
| Endosomal escape peptide L2 | Peptide that assists siRNA delivery | Improves siRNA functional delivery |
| Seed-pairing destabilized GalNAc-siRNA | Chemically modified siRNA with reduced off-target binding | Clinical safety optimization |
How Is siRNA binding Regulated?
siRNA binding is regulated at multiple levels. In C. elegans, the RNA-binding protein RDE-4 is required for Argonaute-siRNA loading, making it a positive regulator of the function. Chemical modifications such as seed-pairing destabilization can attenuate off-target binding while preserving on-target interactions, effectively tuning the specificity of siRNA binding. Delivery vehicle composition, including lipid nanoparticles, GalNAc conjugates, Bicycle peptides, and protein nanocarriers, regulates access of siRNA to cellular compartments and therefore modulates functional binding [1,2,3,7,8]. Polymer-siRNA binding strength can be varied, but this alone does not predict silencing, indicating that downstream regulatory steps constrain the functional outcome.
siRNA binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AGO2 | Cancer and RNAi dysfunction | Knockout and point-mutation cell models |
| TFR1 | Muscle disorders | Knock-in reporter for Bicycle peptide binding |
| ASGPR | Liver metabolic disease | GalNAc-siRNA uptake assays |
| Protein nanocarrier targets | Glioblastoma | Knockout of lysosomal escape pathways |
| Polymer carrier systems | Delivery-limiting disease models | Overexpression of siRNA-binding polymers |
Cancer
Lipid nanoparticles that bind siRNA are being developed for cancer treatment, where siRNA binding enables delivery of silencing RNA to tumor cells. Bioengineered protein nanocarriers that bind siRNA and escape lysosomes have been tested for targeted RNAi therapy in glioblastoma. These approaches depend on efficient siRNA binding to protect the RNA and deliver it intracellularly [1,7].
Metabolic and liver disease
GalNAc-siRNA conjugates bind siRNA and target hepatocytes through the asialoglycoprotein receptor, enabling liver-directed RNAi therapeutics. Seed-pairing destabilization of GalNAc-siRNA conjugates has been used to improve clinical safety by reducing off-target binding. These examples show how siRNA binding chemistry translates into disease-modifying drugs [2,5].
Neuromuscular disease
Conjugation to a transferrin receptor 1-binding Bicycle peptide enhances siRNA potency in skeletal and cardiac muscles, expanding the reach of siRNA binding beyond the liver. This strategy addresses muscle-related disorders where efficient siRNA delivery has been challenging.
Delivery-limiting conditions
Modulating polymer-siRNA binding does not promote polyplex-mediated silencing, underscoring that disease applications require more than strong binding. Similarly, hexahistidine-metal assemblies with RNA-binding and endosomal escape peptides improve siRNA delivery, highlighting the need to optimize binding and release together.
From siRNA binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is AGO2 required for siRNA binding and silencing? | AGO2 knockout cell line |
| Does RDE-4 regulate Argonaute-siRNA loading? | RDE-4 knockout in C. elegans |
| Can seed-pairing destabilization reduce off-target binding? | Point-mutation or chemically modified siRNA in hepatocytes |
| Does TFR1 binding enhance muscle siRNA potency? | TFR1 knock-in reporter in skeletal muscle cells |
| Does lysosomal escape improve glioblastoma RNAi? | Knockout of lysosomal retention pathways |
| Does polymer-siRNA binding strength predict silencing? | Overexpression of polymer-binding modules |
How to Study the siRNA binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA immunoprecipitation | Physical binding of proteins to siRNA | Argonaute-siRNA loading studies |
| Fluorescence polarization | Binding affinity and specificity | Seed-pairing destabilization analysis |
| Reporter gene silencing | Functional RNAi activity | Polymer-siRNA binding versus silencing |
| Live-cell imaging | siRNA trafficking and endosomal escape | Protein nanocarrier evaluation |
| GalNAc conjugation assays | Hepatocyte targeting | Liver-directed siRNA therapeutics |
| Bicycle peptide conjugation | Muscle potency enhancement | Skeletal and cardiac muscle delivery |
| Lipid nanoparticle formulation | Encapsulation and delivery | Cancer siRNA therapy |
| Metal assembly delivery | Endosomal escape and binding | Hexahistidine-metal siRNA delivery |
RNA immunoprecipitation and pull-down
RNA immunoprecipitation can detect physical binding between proteins and siRNA, providing direct evidence for GO:0035197. In C. elegans, RDE-4 association with Argonaute-siRNA complexes has been resolved through genetic and biochemical approaches. Pull-down assays with biotinylated siRNA can identify novel siRNA-binding proteins.
Fluorescence-based binding assays
Fluorescence polarization and anisotropy measure siRNA binding affinity and can quantify the effect of seed-pairing destabilization on target recognition. These methods are useful for comparing delivery vehicles such as lipid nanoparticles and GalNAc conjugates [1,2].
Functional silencing assays
Reporter gene assays and endogenous knockdown experiments measure the downstream consequence of siRNA binding. Polymer-siRNA binding studies show that binding strength alone does not predict silencing, so functional assays are essential. Glioblastoma and muscle models have been used to test whether improved binding translates into therapeutic benefit [3,7].
Delivery and trafficking imaging
Live-cell imaging of labeled siRNA can track binding, uptake, and endosomal escape. Protein nanocarriers that facilitate lysosomal escape have been visualized in glioblastoma models. Hexahistidine-metal assemblies with endosomal escape peptides have also been evaluated for improved delivery.
How CRISPR Can Be Used to Study GO:0035197 siRNA binding
Knockout
CRISPR knockout of Argonaute genes or RDE-4 can abolish siRNA binding and RNAi, providing causal evidence for GO:0035197. Knockout of delivery-related receptors such as TFR1 or ASGPR can test whether specific binding interactions are required for siRNA uptake and potency [2,3].
Point Mutation
Point mutations in the siRNA-binding pocket of Argonaute proteins can dissect which residues mediate guide-strand binding and seed pairing. Point mutations that destabilize seed pairing have been modeled chemically to improve safety of GalNAc-siRNA conjugates.
Knock-in
Knock-in of tagged Argonaute or RDE-4 alleles enables affinity purification and imaging of siRNA-binding complexes. Knock-in reporters for TFR1 or ASGPR can quantify binding and uptake of conjugated siRNAs in relevant tissues [2,3].
Overexpression
Overexpression of siRNA-binding proteins or delivery receptors can enhance RNAi responses and test sufficiency of binding. Overexpression of polymer-binding modules has been used to probe whether increased siRNA binding promotes silencing, with results showing that binding alone is insufficient.
How EDITGENE Supports siRNA binding Research
Researchers studying siRNA binding-related genes often need to determine whether a candidate gene is causally involved in guide-strand loading, target recognition, or delivery. EDITGENE provides CRISPR-based cell models and screening services to test these hypotheses with publication-grade rigor.
Contact EDITGENE today to design your custom CRISPR model for siRNA binding research.
Frequently Asked Questions About siRNA binding
What is siRNA binding?
siRNA binding is the molecular function GO:0035197, defined as binding to a small interfering RNA of 21-23 nucleotides that is processed from double-stranded RNA by an RNAse enzyme.
What genes are involved in siRNA binding?
Key genes include Argonaute family members such as AGO1 and AGO2, the RNA-binding protein RDE-4, and delivery-related receptors such as TFR1 and ASGPR [2,3,4].
What is the GO ID for siRNA binding?
The GO ID for siRNA binding is GO:0035197, under the molecular_function ontology.
How does Argonaute load siRNA?
Argonaute binds siRNA duplexes and retains a guide strand; in C. elegans this loading requires the RNA-binding protein RDE-4.
Why does siRNA binding matter for RNAi therapeutics?
Binding determines delivery, potency, and safety of siRNA drugs such as lipid nanoparticles and GalNAc conjugates [1,2,5].
Does stronger siRNA binding always increase silencing?
No; modulating polymer-siRNA binding does not necessarily promote polyplex-mediated silencing, so binding must be balanced with release and processing.
How can I study siRNA binding in the lab?
Common methods include RNA immunoprecipitation, fluorescence polarization, reporter silencing assays, and live-cell imaging [4,5,6,7].
What diseases are linked to siRNA binding?
Cancer, liver metabolic disease, neuromuscular disorders, and glioblastoma are among the disease areas where siRNA binding is being targeted [1,2,3,7].
Can CRISPR knockout help study siRNA binding?
Yes; knockout of Argonaute or RDE-4 abolishes siRNA binding and RNAi, providing causal evidence.
What delivery systems bind siRNA?
Lipid nanoparticles, GalNAc conjugates, Bicycle peptides, polymer carriers, and protein nanocarriers all bind siRNA [1,2,3,6,7,8].
Conclusion
GO:0035197 siRNA binding is a molecular function that connects the physical recognition of 21-23 nucleotide siRNAs to RNA interference and therapeutic RNA delivery. Argonaute proteins and accessory factors such as RDE-4 define the endogenous machinery, while lipid nanoparticles, GalNAc conjugates, Bicycle peptides, and protein nanocarriers extend the function into medicine [1,2,3,4,7,8]. Because binding strength alone does not guarantee silencing, functional and safety studies remain essential [5,6]. CRISPR-based models and screening provide the tools to dissect these mechanisms and translate them into new RNAi therapies.
References
- 1. El Moukhtari SH et al.. 2023. Lipid nanoparticles for siRNA delivery in cancer treatment.. J Control Release 361:130-146 PMID: 37532145
- 2. Springer AD et al.. 2018. GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.. Nucleic Acid Ther 28(3):109-118 PMID: 29792572
- 3. Østergaard ME et al.. 2025. Conjugation to a transferrin receptor 1-binding Bicycle peptide enhances ASO and siRNA potency in skeletal and cardiac muscles.. Nucleic Acids Res 53(7) PMID: 40207629
- 4. Knittel TL et al.. 2025. Argonaute-siRNA loading via the RNA-binding protein RDE-4 in C. elegans.. Curr Biol 35(23):5897-5907.e6 PMID: 41260219
- 5. Schlegel MK et al.. 2022. From bench to bedside: Improving the clinical safety of GalNAc-siRNA conjugates using seed-pairing destabilization.. Nucleic Acids Res 50(12):6656-6670 PMID: 35736224
- 6. Splichal RC et al.. 2021. Modulating Polymer-siRNA Binding Does Not Promote Polyplex-Mediated Silencing.. Nucleic Acid Ther 31(3):229-236 PMID: 32749923
- 7. Jin Y et al.. 2025. Bioengineered protein nanocarrier facilitating siRNA escape from lysosomes for targeted RNAi therapy in glioblastoma.. Sci Adv 11(8):eadr9266 PMID: 39970222
- 8. Zhang Y et al.. 2024. RNA-binding peptide and endosomal escape-assisting peptide (L2) improved siRNA delivery by the hexahistidine-metal assembly.. J Mater Chem B 12(40):10309-10319 PMID: 39282740
